What is the difference between ALIROCUMAB and FENOFIBRATE?

ALIROCUMAB is a PCSK9 Inhibitor and FENOFIBRATE is a Fibrate. They reach a similar treatment goal through different pharmacological mechanisms, which is why one may be tolerated by a patient who could not tolerate the other.

Is Praluent the same as Fenofibrate?

No. Praluent (ALIROCUMAB) and Fenofibrate (FENOFIBRATE) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, ALIROCUMAB or FENOFIBRATE?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from ALIROCUMAB to FENOFIBRATE?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

ALIROCUMAB vs FENOFIBRATE

Compare ALIROCUMAB (Praluent) and FENOFIBRATE (Fenofibrate) — clinical data, side effects, and patient experiences.

ALIROCUMAB

Praluent · PCSK9 Inhibitor

How it works

12.1 Mechanism of Action Alirocumab is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein (...

Approved for

1 INDICATIONS AND USAGE PRALUENT ® is indicated: To reduce the risk of major adverse cardiovascular (CV) events (coronary heart disease death

myocardial infarction

stroke

myocardial infarction

SubcutaneousTablet

FENOFIBRATE

Fenofibrate, Tricor, Fenoglide · Fibrate

How it works

12.1 Mechanism of Action The active moiety of fenofibrate is fenofibric acid. The pharmacological effects of fenofibric acid in both animals and humans have been extensively studie...

Approved for

1 INDICATIONS AND USAGE Fenofibrate tablet USP is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C

Total-C

TG and Apo B

total cholesterol (Total-C)

OralTablet

Quick Comparison

ALIROCUMABFENOFIBRATE

Drug Class

PCSK9 Inhibitor

Fibrate

Route

Subcutaneous

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ALIROCUMAB

Muscle Pain

>10%

Injection Site Pain

1-10%

Joint Pain

1-10%

Fatigue

1-10%

Limb Pain

1-10%

Diarrhea

1-10%

Headache

1-10%

Cough

0.1-1%

FENOFIBRATE

Nausea

1-10%

Fatigue

1-10%

Diarrhea

1-10%

Drug Not Working

1-10%

Shortness of Breath

1-10%

Headache

1-10%

Dizziness

1-10%

Weakness

1-10%

FDA Warnings

ALIROCUMAB

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions: hypersensitivity vasculitis, angioedema, and other hypersensitivity reactions requiring hospitalization, have been reported with PRALUENT treatment
If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to alirocumab or any excipient in PRALUENT [see Contraindications (4) ]

FENOFIBRATE

5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Serious drug-induced liver injury, including liver transplantation and death, has been reported with fenofibrate
Risks are increased during co-administration with a statin (with a significantly higher rate observed for gemfibrozil), particularly in elderly patients and patients with diabetes, renal failure, or hypothyroidism ( 5
Cholelithiasis: Fenofibrate increases cholesterol excretion into the bile, leading to risk of cholelithiasis
The Action to Control Cardiovascular Risk in Diabetes Lipid (ACCORD Lipid) trial was a randomized placebo-controlled study of 5518 patients with type 2 diabetes mellitus on background statin therapy treated with fenofibrate

Community Sentiment Analysis

Based on 5 Reddit discussions

ALIROCUMAB

positive

0 threads

FENOFIBRATE

positive

5 threads

Community Discussions

No community discussions found for ALIROCUMAB yet.

Community Discussions

5 Reddit threads analysed for FENOFIBRATE

Overall Sentiment

Mixed

Comparison Threads

Avg Post Score

17 upvotes

Patient Experiences (r/pharmacy, r/AskDocs & more)

Why are there so many different strengths of fenofibrate?

Tablets: 40, 48, 54, 120, 145, & 160mg Capsules: 43, 50, 67, 130, 134, 150, & 200mg Micronized caps: 30 & 90mg

r/pharmacy66224y ago

Mishearing a Drug Name

Was reviewing a patient's medical chart. Thought to myself "Man I wonder if anyone mixed up Fenofibrate and Phenobarb". Any times when you or someone you know mixed up two sound alike drugs?

r/pharmacy10101y ago

Fenofibrate v.s. Feno-Super v.s. Feno-Micro

Besides the different doses offered with each formulation, does anyone know the difference between these three forms of fenofibrate? They're not interchangeable with each other either.

r/pharmacy659y ago

Fenofibrate and Zetia

Has anyone seen this combination used in the retail setting? The Zetia package insert states these can be used in combination, but I was just wondering how that translates to real life.

r/pharmacy3912y ago

How to use FDA orange book?

I know we can use FDA orange book to find an approved generic substitution for certain meds with different release mechanism like diltiazem, fenofibrate. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM071436.pdf I am been looking at the orange book and still not sure what is the b

r/pharmacy2410y ago

Community discussions are sourced from public Reddit threads. Content reflects individual opinions and is not medical advice.

ALIROCUMAB vs FENOFIBRATE: What You Should Know

Key Differences

ALIROCUMAB is a PCSK9 Inhibitor, while FENOFIBRATE belongs to the Fibrate class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. ALIROCUMAB is administered via Subcutaneous, whereas FENOFIBRATE uses Oral. Route of administration can affect onset of action and patient adherence.

Safety Considerations

ALIROCUMAB carries 4 FDA warnings. FENOFIBRATE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

FENOFIBRATE vs GEMFIBROZIL→ALIROCUMAB vs Atorvastatin→Atorvastatin vs FENOFIBRATE→ALIROCUMAB vs Rosuvastatin→FENOFIBRATE vs Rosuvastatin→ALIROCUMAB vs SIMVASTATIN→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

ALIROCUMAB: DailyMed label · FAERS adverse events · ClinicalTrials.gov
FENOFIBRATE: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

ALIROCUMAB vs FENOFIBRATE

Compare ALIROCUMAB (Praluent) and FENOFIBRATE (Fenofibrate) — clinical data, side effects, and patient experiences.

ALIROCUMAB

Praluent · PCSK9 Inhibitor

How it works

12.1 Mechanism of Action Alirocumab is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein (...

Approved for

1 INDICATIONS AND USAGE PRALUENT ® is indicated: To reduce the risk of major adverse cardiovascular (CV) events (coronary heart disease death

myocardial infarction

stroke

myocardial infarction

SubcutaneousTablet

FENOFIBRATE

Fenofibrate, Tricor, Fenoglide · Fibrate

How it works

12.1 Mechanism of Action The active moiety of fenofibrate is fenofibric acid. The pharmacological effects of fenofibric acid in both animals and humans have been extensively studie...

Approved for

1 INDICATIONS AND USAGE Fenofibrate tablet USP is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C

Total-C

TG and Apo B

total cholesterol (Total-C)

OralTablet

Quick Comparison

ALIROCUMABFENOFIBRATE

Drug Class

PCSK9 Inhibitor

Fibrate

Route

Subcutaneous

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ALIROCUMAB

Muscle Pain

>10%

Injection Site Pain

1-10%

Joint Pain

1-10%

Fatigue

1-10%

Limb Pain

1-10%

Diarrhea

1-10%

Headache

1-10%

Cough

0.1-1%

FENOFIBRATE

Nausea

1-10%

Fatigue

1-10%

Diarrhea

1-10%

Drug Not Working

1-10%

Shortness of Breath

1-10%

Headache

1-10%

Dizziness

1-10%

Weakness

1-10%

FDA Warnings

ALIROCUMAB

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions: hypersensitivity vasculitis, angioedema, and other hypersensitivity reactions requiring hospitalization, have been reported with PRALUENT treatment
If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to alirocumab or any excipient in PRALUENT [see Contraindications (4) ]

FENOFIBRATE

5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Serious drug-induced liver injury, including liver transplantation and death, has been reported with fenofibrate
Risks are increased during co-administration with a statin (with a significantly higher rate observed for gemfibrozil), particularly in elderly patients and patients with diabetes, renal failure, or hypothyroidism ( 5
Cholelithiasis: Fenofibrate increases cholesterol excretion into the bile, leading to risk of cholelithiasis
The Action to Control Cardiovascular Risk in Diabetes Lipid (ACCORD Lipid) trial was a randomized placebo-controlled study of 5518 patients with type 2 diabetes mellitus on background statin therapy treated with fenofibrate

Community Sentiment Analysis

Based on 5 Reddit discussions

ALIROCUMAB

positive

0 threads

FENOFIBRATE

positive

5 threads

Community Discussions

No community discussions found for ALIROCUMAB yet.

Community Discussions

5 Reddit threads analysed for FENOFIBRATE

Overall Sentiment

Mixed

Comparison Threads

Avg Post Score

17 upvotes

Patient Experiences (r/pharmacy, r/AskDocs & more)

Why are there so many different strengths of fenofibrate?

Tablets: 40, 48, 54, 120, 145, & 160mg Capsules: 43, 50, 67, 130, 134, 150, & 200mg Micronized caps: 30 & 90mg

r/pharmacy66224y ago

Mishearing a Drug Name

Was reviewing a patient's medical chart. Thought to myself "Man I wonder if anyone mixed up Fenofibrate and Phenobarb". Any times when you or someone you know mixed up two sound alike drugs?

r/pharmacy10101y ago

Fenofibrate v.s. Feno-Super v.s. Feno-Micro

Besides the different doses offered with each formulation, does anyone know the difference between these three forms of fenofibrate? They're not interchangeable with each other either.

r/pharmacy659y ago

Fenofibrate and Zetia

Has anyone seen this combination used in the retail setting? The Zetia package insert states these can be used in combination, but I was just wondering how that translates to real life.

r/pharmacy3912y ago

How to use FDA orange book?

r/pharmacy2410y ago

Community discussions are sourced from public Reddit threads. Content reflects individual opinions and is not medical advice.

ALIROCUMAB vs FENOFIBRATE: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.